Every year 1.35m babies wordwide are born with a congenital heart defect. 400,000 of them suffer from a heart valve defect but currently there is no durable valve replacement available on the market. We are planning to meet that clinical demand with a completely new prosthetic valve for adults and children which is implanted using a low-risk transcatheter technique. Our valve is made from patient-donated (endogenous) tissue, giving it a life-long durability: a once-in-a-lifetime solution that is affordable for both patients and healthcare providers worldwide.Learn more
GrOwnValve is a pre-clinical stage medical device company, developing a unique heart valve prosthesis system. Our AdultValve and ChildValve are made from the patients‘ own tissue and, including a bioresorbable anchoring device, will be available as part of a procedure pack that enables a safe, affordable and easy-to-use minimally invasive heart valve replacement.
Our main goal is to offer a lifelong cure to patients worldwide who have heart valve defects. Our innovation eliminates the need for patients to undergo repetative heart valve replacement surgery and to accept medication throughout their whole lives.
Engineer 3D Technology
QM Production and Process Quality
Regulatory and Business Development
Research and Development Engineer
We are glad to announce that we got funded by the DZHK for conducting our first clinical trial in adult patients starting in 2022.
We are very happy to be nominated #ScienceBreakthrough of the year by the Falling Walls Foundation award!
In 2019 Spark helped kick-start the bioresorbable stent solution to make the GrOwnValve innovation a possible treatment for small (growing) patients.
In july 2018 the GrOwnValve Project Team won the BPW Canvas business plan price by the IBB Berlin.
We are very proud to have been able to be part of the research consortium that was able to reach a Sciencemag publication.
In Autumn of 2017 the GrOwnValve Project was rewarded the EXIST translational grant to bring the innovative technology into preclinical testing.
Our co-founder Jasper Emeis was interviewed about the win of the EIC by the Healthcapital online-magazin.
GrOwnValve wins the INAM Innovation Challenge 2021.
From August 2021 the EXIST II funding programme supported GrOwnValve for one year to establish Quality and Risk Management.
In November 2021, our project „Kleine Patienten – großer Bedarf“, administered by VDI, received funding by the German Federal Ministery of Education and Research.
Since April 2022, the EIC Accelerator Programme has helped with the transition of our products from research objects to their clinical application.
We are proud and happy to announce that our first clinical trial in (young) adult patients, starting in 2023, has received funding by the DZHK.
German nationwide broadcaster ZDF published a documentary on the topic of cardiac health, featuring GrOwnValve as an example of cutting edge RnD (from 37:00 onwards).